State Street Corp reduced its stake in shares of Cencora, Inc. (NYSE:COR – Free Report) by 63.4% in the third quarter, HoldingsChannel.com reports. The firm owned 9,203,262 shares of the company’s stock after selling 15,926,511 shares during the period. State Street Corp’s holdings in Cencora were worth $2,763,279,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Elevation Wealth Partners LLC boosted its position in shares of Cencora by 506.2% during the second quarter. Elevation Wealth Partners LLC now owns 97 shares of the company’s stock valued at $27,000 after buying an additional 81 shares during the last quarter. Bell Investment Advisors Inc bought a new stake in Cencora during the second quarter worth $28,000. Caitlin John LLC bought a new stake in Cencora during the second quarter worth $28,000. Meeder Asset Management Inc. raised its position in Cencora by 157.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 98 shares of the company’s stock valued at $29,000 after buying an additional 60 shares during the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. raised its position in Cencora by 192.1% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 111 shares of the company’s stock valued at $33,000 after buying an additional 73 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of research firms have issued reports on COR. Evercore reaffirmed an “outperform” rating and set a $350.00 price objective (up from $330.00) on shares of Cencora in a report on Thursday, August 6th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $330.00 target price on shares of Cencora in a research note on Tuesday, September 8th. Wells Fargo & Company increased their target price on shares of Cencora from $395.00 to $400.00 and gave the company an “overweight” rating in a report on Tuesday, November 17th. Weiss Ratings raised shares of Cencora from a “buy (b-)” rating to a “buy (b)” rating in a research report on Tuesday, October 6th. Finally, Argus boosted their price target on shares of Cencora from $340.00 to $380.00 and gave the stock a “buy” rating in a report on Tuesday, October 20th. Thirteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $381.00.
Check Out Our Latest Stock Report on Cencora
Insiders Place Their Bets
In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of the firm’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $324.12, for a total value of $3,662,556.00. Following the completion of the sale, the executive vice president directly owned 19,455 shares of the company’s stock, valued at $6,305,754.60. This trade represents a 36.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.38% of the company’s stock.
Cencora Price Performance
COR opened at $339.05 on Friday. The firm has a market cap of $64.70 billion, a P/E ratio of 18.92, a PEG ratio of 1.75 and a beta of 0.58. The firm has a 50-day moving average of $329.42 and a 200 day moving average of $316.95. The company has a debt-to-equity ratio of 3.01, a quick ratio of 0.59 and a current ratio of 0.94. Cencora, Inc. has a fifty-two week low of $244.82 and a fifty-two week high of $377.54.
Cencora (NYSE:COR – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $4.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.58 by $0.08. The business had revenue of $88.35 billion during the quarter, compared to the consensus estimate of $87.95 billion. Cencora had a net margin of 1.03% and a return on equity of 110.72%. The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the company posted $3.84 earnings per share. On average, research analysts expect that Cencora, Inc. will post 19.58 EPS for the current year.
Cencora Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 30th. Shareholders of record on Friday, November 13th will be issued a dividend of $0.66 per share. This represents a $2.64 annualized dividend and a yield of 0.8%. This is a positive change from Cencora’s previous quarterly dividend of $0.60. The ex-dividend date of this dividend is Friday, November 13th. Cencora’s dividend payout ratio is currently 14.73%.
Cencora Profile
Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers. The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.
See Also
- Five stocks we like better than Cencora
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
